Minimal clinically important difference in Alzheimer's disease: Rapid review

Abstract

AbstractINTRODUCTIONWe conducted a rapid systematic review of minimal clinically important differences (MCIDs) for Alzheimer's disease (AD) trial endpoints.METHODSTwo reviewers searched EMBASE, MEDLINE, and PubMed from inception to June 4, 2023.RESULTSTen articles were retrieved. For mild cognitive impairment (MCI), a change of +2 to +3 points on the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog), +1 points on the Clinical Dementia Rating scale sum of boxes (CDR‐SB), −5 points on the integrated Alzheimer's Disease Rating Scale (iADRS), or −1 to −2 points on the Mini‐Mental State Examination (MMSE) was considered meaningful. For patients with mild AD, a change of +3 on the ADAS‐Cog, +2 points on CDR‐SB, −9 points on the iADRS, or −2 points on the MMSE was considered meaningful. For patients with moderate to severe AD, a change of +2 points on the CDR‐SB or a change of −1.4 to −3 points on the MMSE was considered meaningful.CONCLUSIONThis review identified previously published MCIDs for AD trial endpoints. Input from patients and caregivers will be needed to derive more meaningful endpoints and thresholds.Highlights This systematic rapid review identified thresholds for minimal clinically important differences (MCIDs) for recently used Alzheimer's disease (AD) trial endpoints: Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog), Clinical Dementia Rating scale sum of boxes (CDR‐SB), integrated Alzheimer's Disease Rating Scale (iADRS), Mini‐Mental State Examination (MMSE). MCIDs were higher for more severe stages of AD. Average treatment effects in recent trials of anti‐amyloid disease modifying monoclonal antibodies are lower than previously published MCIDs. In future trials of disease modifying treatments for AD, the proportion of participants in each treatment group that experienced a clinically meaningful decline could be reported. More work is needed to incorporate the values and preferences of patients and care partners in deriving MCIDs.